How to treat histone 3 altered gliomas: Molecular landscape and therapeutic developments

AV Nguyen, JM Soto, SM Gonzalez, J Murillo… - Biomedicines, 2023 - mdpi.com

The 2021 World Health Organization Classification of Tumors of the Central Nervous System
reflected advances in understanding of the roles of oncohistones in gliomagenesis with the …

被引用次数：5 相关文章所有 7 个版本

[HTML] mdpi.com

[HTML][HTML] Tumor Microenvironment in Gliomas: a treatment hurdle or an opportunity to grab?

V Di Nunno, M Aprile, L Gatto, A Tosoni, L Ranieri… - Cancers, 2023 - mdpi.com

Simple Summary In the present review, we reported the main findings describing tumor-
associated microenvironment in patients with IDH mutated and wild-type gliomas. We also …

被引用次数：6 相关文章所有 7 个版本

[PDF] oup.com

ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

I Arrillaga-Romany, A Lassman, SL McGovern… - Neuro …, 2024 - academic.oup.com

Abstract Background H3 K27M-mutant diffuse glioma primarily affects children and young
adults, is associated with a poor prognosis, and no effective systemic therapy is currently …

被引用次数：5 相关文章所有 10 个版本

[HTML] mdpi.com

[HTML][HTML] From Pediatric to Adult Brain Cancer: Exploring Histone H3 Mutations in Australian Brain Cancer Patients

B Grebstad Tune, H Sareen, B Powter… - Biomedicines, 2023 - mdpi.com

Genetic histone variants have been implicated in cancer development and progression.
Mutations affecting the histone 3 (H3) family, H3. 1 (encoded by HIST1H3B and HIST1H3C) …

被引用次数：2 相关文章所有 12 个版本

[PDF] brainlife.org

[PDF][PDF] ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma Isabel Arrillaga-Romany1 …

RS Tarapore, PY Wen, T Cloughesy10 - 2024 - brainlife.org

Abstract Background: H3 K27M-mutant diffuse glioma primarily affects children and young
adults, is associated with a poor prognosis, and no effective systemic therapy is currently …